BridgeBio Pharma, Inc. (BBIO) Balance Sheet

The balance sheet is strengthening on the asset side, with cash rising from about $547M to $1.5B, but total liabilities have grown from roughly $1.9B to $3.8B over the same window. This divergence suggests the company is funding its operations and growth through obligations rather than retained earnings, which may warrant closer scrutiny of the financing mix. Investors should monitor whether the deficit narrows as commercial revenue scales or continues to widen under sustained losses.

With total debt of $2.5B against cash of $1.5B, net debt remains substantial relative to the company's reported operating cash burn. The negative equity position means conventional leverage ratios offer limited comfort, and the reported debt figures appear to have fluctuated materially across recent quarters, including a peak near $3.4B in 2026Q1. This pattern may indicate reliance on capital market access, and the timing and terms of any refinancing warrant further investigation.

The sharp cash increase in the latest quarter appears to reflect a combination of operating inflows and financing activity, though the composition is not fully separable from the reported figures alone. A current ratio above 2.0 indicates reasonable short-term coverage, but the prior quarter's ratio of 1.23 shows how quickly this buffer has been volatile. The adequacy of runway should be judged against forward cash burn, which the reported quarterly data suggests remains negative.

The steady expansion of accumulated deficit reflects persistent net losses across the reported period, consistent with the company's negative margins. Concurrent share repurchases reported in recent quarters, despite negative free cash flow, raise questions about capital allocation priorities relative to balance sheet repair. Investors should monitor whether equity deterioration stabilizes once revenue growth translates into sustained profitability.